Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSAInterventions for cellulitis and erysipelasTigecycline: first of a new class of antimicrobial agentsEfficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infectionsTigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infectionsA randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Evaluation of a potential tigecycline-warfarin drug interaction.Acute pancreatitis related to tigecycline: case report and review of the literature.Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.Excess deaths associated with tigecycline after approval based on noninferiority trials.Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.Tigecycline for the treatment of infections due to resistant Gram-positive organisms.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.Tigecycline does not prolong corrected QT intervals in healthy subjects.Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.Current challenges in treating MRSA: what are the options?An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Newer developments in the treatment of Gram-positive infections.Emerging drugs for complicated skin and skin-structure infections.Efficacy and safety of tigecycline: a systematic review and meta-analysis.Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.Novel antibiotics for the treatment of Staphylococcus aureus.Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus.Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals.Characteristics of superinfections during treatment with tigecycline.In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.Comparative analysis of empiric antimicrobial treatments for skin and soft tissue infections in newly hospitalized patients.Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designDetermination of tigecycline in human skin using a novel validated LC-MS/MS method.Clarification to the systematic review and meta-analysis involving tigecycline.
P2860
Q22305769-4D605B43-A09B-4F6C-974D-30695403181DQ24234864-DBA10C77-9BEB-4365-AB7F-6D4A7DD1D674Q28253736-5B9F1DE0-2C36-422A-BFC7-3BF7F94AC611Q33642184-219AAE57-81ED-41D6-9A04-7EEA9216B591Q33746042-38840CD3-6D79-46B1-AC77-C0F5F04F70D1Q33770721-AB658961-C055-4865-8B86-141BB486D35BQ33776590-93A6CBEA-1669-4812-BCCB-A14C9F2E6F1FQ34352287-0AF77520-3E3F-4FF0-AD67-73872902C63EQ34474973-A54FC7C3-F76C-4F30-BBCF-4793465B3BFAQ34478074-0E6E1625-8E48-4476-8783-52A615ECC144Q34593514-50377067-17AC-4A10-A9A5-302422F3154AQ34599630-577C4341-BFE6-441B-808C-EF174583F422Q35026616-039F0895-616C-4745-9ACD-907B35EB72AFQ35876393-1547C854-E132-46FA-8F2D-386D97F51BEDQ36115632-2CE2572F-9D5E-4FA8-B9A8-A56B64AB8088Q36312071-B8C9AC20-4177-431A-9F87-151D9B0FA7E9Q36312075-F1C26D5F-F739-4D5D-92EB-76FA7253D96BQ36376443-7B2BD183-9F83-4FD4-8F93-60194096EAFCQ36663656-FEDD6313-C383-441B-8453-A7230D623CFEQ36744813-95CF76BF-6691-4979-A429-D98A85F7E532Q36757583-C4FF3B5D-5970-4033-BDBA-D4773E09E509Q36967265-4482E28D-6DF9-4CD9-9680-C2F84039C00FQ37291338-95433CFA-8838-4587-9259-251043E7E8F6Q37563029-C8B8FA37-EDBB-4BC4-8D21-F6E176C0F6D7Q37636151-8B32E1DC-6ECC-40D5-8C4D-880FF1AAF069Q37765900-B976409F-6F38-42DF-BCB1-DC19CD3C240AQ37891606-421F7B9B-6720-41CB-A516-263D120781DEQ37924980-B9CD8008-FBCF-4221-970F-F1F311BCFC8FQ38255278-0521A9A7-DCC5-4457-95AB-48AE8E9C2C9CQ39222597-9DD3512A-1C4D-4C1F-B184-BBD43B2DE112Q39933945-2DB31ABC-A88D-431F-BE85-CCE739FC7811Q40014144-28CF8A1E-2545-4CE8-A08D-297E8CE4126FQ40236833-9BEDD291-E5EC-44C7-8943-80ACEBA3060DQ40714785-62F52FAB-3E2D-4C0E-93C3-D28B3849D576Q41904163-01CE16EF-EC53-44C6-902E-8D58F534A5C4Q42246119-FF087D86-AF3F-4EA8-A490-00367B12BD55Q42262776-E1B7F7BF-6284-4216-87C7-3328F08096A1Q42544277-8647E395-DF2E-4C21-846B-EBCD04100BA6Q42807231-2DC66F4B-854C-4565-9010-E8750E1092C4Q42931315-0F68C454-D980-4F69-B025-B02E2EBF84D0
P2860
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@en
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@nl
type
label
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@en
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@nl
prefLabel
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@en
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@nl
P2093
P1476
Efficacy and safety of tigecyc ...... andomized, double-blind trial.
@en
P2093
Daniel Curcio
Evelyn Ellis-Grosse
Gilbert Rose
John M Embil
Maria E Campos
Robert L Penn
Sarvajna Sacchidanand
P304
P356
10.1016/J.IJID.2005.05.003
P577
2005-09-01T00:00:00Z